Advanced search
Start date
Betweenand
Related content
(Reference retrieved automatically from Web of Science through information on FAPESP grant and its corresponding number as mentioned in the publication by the authors.)

Artemisinin-type drugs for the treatment of hematological malignancies

Full text
Author(s):
Mancuso, I, R. ; Foglio, M. A. [1] ; Saad, S. T. Olalla [2]
Total Authors: 3
Affiliation:
[1] Univ Estadual Campinas, Fac Pharmaceut Sci, UNICAMP, Campinas, SP - Brazil
[2] Mancuso, R., I, Univ Estadual Campinas, Hematol & Hemotherapy Ctr, HEMOCTR UNICAMP, Campinas, SP - Brazil
Total Affiliations: 2
Document type: Review article
Source: Cancer Chemotherapy and Pharmacology; v. 87, n. 1 NOV 2020.
Web of Science Citations: 1
Abstract

Qinghaosu, known as artemisinin (ARS), has been for over two millennia, one of the most common herbs prescribed in traditional Chinese medicine (TCM). ARS was developed as an antimalarial drug and currently belongs to the established standard treatments of malaria as a combination therapy worldwide. In addition to the antimalarial bioactivity of ARS, anticancer activities have been shown both in vitro and in vivo. Like other natural products, ARS acts in a multi-specific manner also against hematological malignancies. The chemical structure of ARS is a sesquiterpene lactone, which contains an endoperoxide bridge essential for activity. The main mechanism of action of ARS and its derivatives (artesunate, dihydroartemisinin, artemether) toward leukemia, multiple myeloma, and lymphoma cells comprises oxidative stress response, inhibition of proliferation, induction of various types of cell death as apoptosis, autophagy, ferroptosis, inhibition of angiogenesis, and signal transducers, as NF-kappa B, MYC, amongst others. Therefore, new pharmaceutically active compounds, dimers, trimers, and hybrid molecules, could enhance the existing therapeutic alternatives in combating hematologic malignancies. Owing to the high potency and good tolerance without side effects of ARS-type drugs, combination therapies with standard chemotherapies could be applied in the future after further clinical trials in hematological malignancies. (AU)

FAPESP's process: 17/21801-2 - Predictors of severity and new treatments for bone marrow neoplasias
Grantee:Sara Teresinha Olalla Saad
Support Opportunities: Research Projects - Thematic Grants
FAPESP's process: 16/18384-8 - Development of patches containing the association of artemether-lumefantrine for the treatment of malaria caused by Plasmodium falciparum
Grantee:Fabiana Volpe Zanutto
Support Opportunities: Scholarships abroad - Research Internship - Doctorate
FAPESP's process: 14/16008-3 - Development of patches containing the association of artemether - lumefantrine for the treatment of malaria caused by Plasmodium falciparum
Grantee:Fabiana Volpe Zanutto
Support Opportunities: Scholarships in Brazil - Doctorate